Vilya is at the forefront of computational biotechnology, leveraging advanced computational methods to create a new class of medicines that precisely target disease biology. Their innovative platform is rooted in groundbreaking research that explores uncharted chemical space, allowing for the design of novel molecular structures that do not exist in nature. This approach enables Vilya to develop molecules with enhanced drug-like properties, aiming to tackle previously insurmountable targets across various medical indications. The company's vision is to revolutionize the drug development process by making traditional high-throughput screening methods obsolete, ultimately striving to cure diseases through their advanced computational techniques.

The foundation of Vilya's technology is built on the expertise of its co-founders, including Dr. David Baker from the Institute of Protein Design, who has significantly contributed to the field of protein engineering. Vilya's commitment to innovation is further demonstrated by their recent achievements, such as securing substantial financing to advance their computational drug design efforts and publishing research that validates their approach to designing chemically diverse macrocycles. This combination of cutting-edge research and a strong scientific team positions Vilya to make significant strides in the development of transformative therapies.

United States

Vilya is a computational biotechnology company creating a novel class of medicines to precisely target disease biology. The company’s proprietary platform, powered by advanced machine learning, taps into uncharted chemical space to design de novo molecular structures with enhanced drug-like properties that range in size between small molecules and antibodies. Vilya is leveraging its platform to focus on previously difficult-to-drug therapeutic targets. Vilya was co-founded by a team of scientists from the Institute of Protein Design (IPD) led by David Baker, Ph.D., and ARCH Venture Partners. The company has operations in Seattle and South San Francisco.

Vilya

Company Details